WO2005003128A1 - Thiazolylpiperidine derivatives as mtp inhibitors - Google Patents
Thiazolylpiperidine derivatives as mtp inhibitors Download PDFInfo
- Publication number
- WO2005003128A1 WO2005003128A1 PCT/EP2004/005931 EP2004005931W WO2005003128A1 WO 2005003128 A1 WO2005003128 A1 WO 2005003128A1 EP 2004005931 W EP2004005931 W EP 2004005931W WO 2005003128 A1 WO2005003128 A1 WO 2005003128A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- radical
- pharmaceutically acceptable
- formula
- acid
- Prior art date
Links
- 0 *C(C(*)=O)N* Chemical compound *C(C(*)=O)N* 0.000 description 3
- ZLXDECWYKGWVMP-UHFFFAOYSA-N O=C(c1c[s]c(C(CC2)CCN2C(c(cccc2)c2-c2ccc(C(F)(F)F)cc2)=O)n1)N(CC1)CCN1c1c(ccnc2)c2ccn1 Chemical compound O=C(c1c[s]c(C(CC2)CCN2C(c(cccc2)c2-c2ccc(C(F)(F)F)cc2)=O)n1)N(CC1)CCN1c1c(ccnc2)c2ccn1 ZLXDECWYKGWVMP-UHFFFAOYSA-N 0.000 description 1
- WPHUUIODWRNJLO-UHFFFAOYSA-O [O-][N+](c1ccccc1[S+](O)(Cl)=O)=O Chemical compound [O-][N+](c1ccccc1[S+](O)(Cl)=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the invention relates to compounds that are inhibitors of microsomal triglyceride transfer protein (MTP), to pharmaceutical compositions comprising same, and to the use thereof in medicine.
- MTP microsomal triglyceride transfer protein
- MTP microsomal triglyceride transfer protein
- enterocytes which catalyses the assembly of biomolecules that transport triglycerides, the apo B lipoproteins.
- apo B more particularly denotes apoprotein 48 of the intestine and apoprotein 100 of the liver.
- Molecules that inhibit MTP and/or the secretion of apo B might thus be useful for the treatment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia associated with diabetes, and also for the prevention of and treating obesity.
- these compounds have an entirely advantageous possible application in the treatment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia associated with diabetes, and also with the prevention and treatment of obesity.
- the present invention relates firstly to compounds of thia- zolylpiperidine structure of the general formula (I):
- A represents a radical chosen from radicals a1 and a2 below: FT ,O. I -R -! ⁇ L ⁇ R° •
- G represents a divalent bond or radical chosen from groups g1 , g2 and g3 below:
- R 1 is chosen from hydrogen and an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl or alkoxycarbonyl radical
- R 2 , R 2' and R 3 which may be identical or different, are chosen, independently of each other, from a hydrogen atom, an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl radical and a radical -NRR'; or • R 2 and R 3 together form, with the nitrogen atom that bears them, a heterocycle
- R 4 and R 5 which may be identical or different, are chosen, independently of each other, from a hydrogen atom, an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl radical and a radical
- halogen atom denotes a fluorine, chlorine, bromine or iodine atom.
- alkyl radicals which may be optionally substituted as indicated above, are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, te/f-butyl, pentyl, isopentyl, neopentyl, 2-methylbutyl, 1-ethylpropyl, hexyl, isohexyl, neo- hexyl, 1-methylpentyl, 3-methylpentyl, 1 ,1-dimethylbutyl, 1 ,3-dimethylbutyl, 1-ethyL butyl, 1-methyl-1-ethylpropyl, heptyl, 1-methylhexyl, 1-pro ⁇ ylbutyl, 4,4-dimethyL pentyl, octyl, 1-methylheptyl, 2-methylhexyl, 5,5-dimethylhexyl, nonyl, decyl
- alkenyl radicals which may be optionally substituted as indicated above, are ethylenyl, propenyl, propadienyl, butenyl, butadienyl, pen- tenyl, pentadienyl, hexenyl, hexadienyl, heptenyl, heptadienyl, octenyl, octadienyl, nonenyl, nonadienyl, decenyl and decadienyl, and also the branched isomers thereof, the absence of indication of the position of the double bond(s) being necessarily understood as meaning that no limitation is placed on the double bond(s).
- the "pentenyl” radical includes, without preference, the pent-1-en-1- y ⁇ , pent-2-en-1-y ⁇ and per.i-3-en-1-y! radicals, but also the pent-1-en-2-yl, pent-2-en-2-yl and pent-3-en-2-yl radicals, as well as the pent-1-en-3-yl, pent-2-en-3-yl and pent-3-en-3-yl radicals.
- alkynyl radicals which may be optionally substituted as indicated above, are ethynyl, propynyl, propadiynyl, butynyl, butadiynyl, pentynyl, pentadiynyl, hexynyl, hexadiynyl, heptynyl, heptadiynyl, octynyl, octadiynyl, nonynyl, nonadiynyl, decynyl and decadiynyl, and also the branched isomers thereof, the absence of indication of the position of the double bond(s) being necessarily understood as meaning that no limitation is placed on the double bond(s).
- the "pentynyl" radical includes, without preference, the pent-1- yn-1-yl, pent-2-yn-1-yl and pent-3-yn-1-yl radicals, but also the pent-1-yn-2-yl, pent-2-yn-2-yl and pent-3-yn-2-yl radicals, as well as the pent-1-yn-3-yl, pent-2-yn-3-yl and pent-3-yn-3-yl radicals.
- cycloalkyl denotes a monocyclic, bicyclic or tricyclic, bridged or unbridged cycloalkyl radical containing from 3 to 13 carbon atoms, optionally comprising one or more double bonds, also including spirane compounds, and optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkyl, especially substituted by one or more halogen atoms, in particular perhaloalkyl, for instance trifluoromethyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, aikyldisulfanyl (alkyl-S-S-), alkyls
- cycloalkyl groups which are optionally substituted as indicated above, are especially cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and cyclodecyl, adamantyl, diamantyl, norbomyl and bornyl groups.
- heterocycloalkyl denotes a monocyclic, bicyclic or tricyclic radical containing a total of from 3 to 13 atoms, among which 1 , 2, 3 or 4 are chosen, independently of each other, from nitrogen, oxygen and sulfur, the other atoms being carbon atoms, the said heterocyclic radical also optionally comprising 1 , 2, 3 or 4 double bonds, also including spirane compounds, and being optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxy] group, and an alkyl, especially substituted by one or more halogen atoms, in particular perhaloalkyl, for instance trifluoromethyl, alkenyl, alkynyl, alkoxy, alkenyl
- saturated or partially unsaturated, monocyclic hetero- cycles of 5 to 8 atoms are saturated, or partially unsaturated, derivatives of the heteroaryls defined later.
- heterocycloalkyl radicals that may be mentioned are morpholino, morpholinyl, piperidyl, thiazolidinyl, oxa- zolidinyb tetrahydrothienyl, tetrahydrofuryl, tetrahydropyranyl, pyrrolidinyl, isoxa- zolidinyl, imidazolidinyl and pyrazolidinyl radicals.
- Aryl radicals that may be mentioned, in a non-limiting manner, include phenyl, naphthyl, anthryl and phenanthryl radicals.
- heteroaryl denotes a monocyclic, bicyclic or tricyclic aromatic radical containing a total of from 3 to 13 atoms, among which 1 , 2, 3 or 4 are chosen, independently of each other, from nitrogen, oxygen and sulfur, optionally in oxidized form (in the case of nitrogen and sulfur), the other atoms being carbon atoms, the said heteroaryl radical being optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R ⁇ which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkyl, especially substituted by one or more halogen atoms, in particular perhaloalkyl, for instance trifluoromethyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alky
- the heterocyclic polycyclic nucleus consists of one or more monocycles each containing from 5 to 8 atoms included in the ring.
- heteroaryl radicals optionally substituted as has just been described, are radicals derived from heteroaromatic compounds, such as pyridine, furan, thiophene, pyrrole, imidazole, thiazole, isothiazole, isoxazole, furazane, pyridazine, pyrimidine, pyrazine, thiazines, oxazole, pyrazole, oxadi- azole, triazole and thiadiazole.
- heteroaromatic compounds such as pyridine, furan, thiophene, pyrrole, imidazole, thiazole, isothiazole, isoxazole, furazane, pyridazine, pyrimidine, pyrazine, thiazines, oxazole, pyrazole, oxadi- azole, triazole and thiadiazole.
- heteroaryls that may be mentioned are pyridyls, pyrimidinyls, triazolyls, thiadiazolyls, oxazolyls, thiazolyls and thienyls.
- bicyclic heteroaryl radicals in which each monocycle contains from 5 to 8 endocyclic atoms are derived from aromatic compounds chosen from indolizine, indole, isoindole, benzofuran, benzothiophene, indazole, benzimidazole, benzothiazole, benzofurazane, benzothiofurazane, purihe, quino- line, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, naphthyridines, pyrazolotriazines, pyrazolopyrimidine and pteridine.
- heteroaryls defined above, quinolyl, pyridyl, benzotri- azolyl, triazolyl, acridyl, phenazinyl and carbazolyl radicals are preferred.
- the said heterocycle is a monocycle, bicycle or tricycle containing a total of from 3 to 13 atoms including the nitrogen atom, among which 1 , 2, 3 or 4 are chosen, independently of each other, from nitrogen, oxygen and sulfur, the other atoms being carbon atoms, the said heterocycle also optionally comprising 1 , 2, 3 or 4 double bonds, also including spirane compounds, and being optionally substituted by one or more chemical species, which may be identical or different, chosen from a halogen atom, an oxo, thioxo, hydroxyl, thiol, -NRR' (in which R and R', which may be identical or different, are as defined above), cyano, nitro or carboxyl group, and an alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio,
- geometrical isomer means a cis/trans or E/Z isomerism. More particularly, the possible double bond(s) present in the various substituents of the compounds of the general formula (I) can be of E or Z configuration. These pure or impure geo- metrical isomers, alone or as a mixture, form an integral part of the compounds of the formula (I).
- optical isomer includes all the isomeric forms, alone or as mixtures, resulting from the presence of one or more axes and/or centres of sym- metry in the molecule, and resulting in the rotation of a beam of polarized light.
- optical isomer more particularly includes enantiomers and disastero- isomers, in pure form or as a mixture.
- the acids capable of forming pharmaceutically acceptable salts with the compounds of the formula (I) above are organic or mineral acids.
- Non-limiting examples that may be mentioned include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, tartaric acid, citric acid, maleic acid, acetic acid, fumaric acid, alkanesulfonic acid, naphthalenesulfonic acid, para-toluenesulfonic acid, bis-trifluoroacetic acid and camphoric acid.
- the bases capable of forming pharmaceutically acceptable salts with the compounds of the formula (I) above are mineral or organic bases.
- non-limiting examples that may be mentioned include sodium hydroxide, potassium hydroxide, ammonia, diethylamine, triethylamine, ethanolamine, diethanolamine, piperidine, piperazine, morpholine, basic amino acids, such as arginine and lysine, osamines, for example meglumine, and amino alcohols, such as 3-aminobutanol and 2-aminobutanol.
- the invention especially covers the pharmaceutically acceptable salts, as indicated above, but also salts allowing a suitable separation or crystalli- zation of the compounds of the formula (I), such as the salts obtained with chiral amines.
- the compounds of the formula (I) above also comprise the prodrugs of these compounds.
- prodrugs means compounds which, once administered to the patient, are chemically and/or biologically converted by the living body into compounds of the formula (I).
- the compounds of the formula (I) according to the invention that are preferred are those for which the radical R 5 represents hydrogen, the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds; and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.
- Another preferred group of compounds according to the present invention consists of compounds of the formula (I) in which the thiazolyl radical is branched in position 3 or in position 4 of the piperidine nucleus, preferably in position 4 of the piperidine nucleus.
- Another preferred group of compounds according to the present invention consists of compounds of the general formula (I) In which G represents the radical g1 , preferably in which Y represents an oxygen atom, the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the sol- vates and hydrates of these compounds; and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.
- G represents the radical g1 , preferably in which Y represents an oxygen atom
- the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the sol- vates and hydrates of these compounds and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.
- Another preferred group of compounds according to the present invention consists of compounds of the general formula (I) in which the radical R 4 represents hydrogen, the radical R 5 represents hydrogen, the thiazolyl radical is branched in position 4 of the piperidine nucleus, and G represents the radical g1 in which Y represents an oxygen atom, the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds; and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.
- Another preferred group of compounds of the invention consists of compounds of the general formula (I) in which R 1 represents an aryl radical, especially phenyl, substituted by one or more aryl and/or alkyl radicals.
- R 1 represents an aryl radical, especially phenyl, substituted by one or more aryl and/or alkyl radicals.
- R 1 represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or propyl, and/or with a perhaloalkyl or perhaloalkoxy radical, are most particularly preferred.
- R represents a substituted biphenyl radical, for example a trifluoromethylbiphenyl or methyltrifluoromethoxy- biphenyl radical, are more particular preferred.
- another preferred group of compounds consists of those for which A represents a2, the other substituents having the same definitions as those given above, the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds; and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.
- R 6 and R 7 which may be identical or different, and independently of each other, have the same definitions as the radicals R 2 and R 3 defined above, the other substituents having the same definitions as those given above, the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds; and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.
- a preferred sub-group of compounds consists of compounds of the general formula (I) in which G represents the radical g1 , with Y representing an oxygen atom, R 1 represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or propyl, and/or a trifluoromethyl or trifluoro ethoxy radical, and A represents a2, the other substituents being as defined above, the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the sol- vates and hydrates of these compounds; and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.
- G represents the radical g1
- R 1 represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or propyl, and/or a triflu
- the compounds that are more particularly preferred are those of the general formula (I) in which G represents the radical g1, with Y representing an oxygen atom, R 1 represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or propyl, and/or a trifluoromethyl or trifluoromethoxy radical, and A represents a2' as defined above, the other substituents being as defined above, the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds; and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds.
- G represents the radical g1
- R 1 represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or propyl, and/or a trifluoro
- Particularly preferred examples of compounds according to the present invention are chosen from: N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl) 2-[1 -(4'-trifluoromethyl- biphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate; - N-ethyl-N-(1-methyl-2-oxo-2-pyrid-3-ylethyl) 2-[1-(4'-trifluoromethyl- biphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate; N-ethyl-N-(1 -methyl-2-oxo-2-phenyiethyl) 2-[1 -(6-methyl-4'-trifluoro- methoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamte; N-ethyl-N-(1-methyl-2-ox
- the compounds of the present invention can be prepared from the compounds of the formula (ll):
- T represents a labile protecting group, for example ferf-butoxy- carbonyl (BOC), and R 5 is as defined above, which is reacted with ethyl R 4 -bromopyruvate, generally in equimolar proportions, in a polar solvent, for example dimethylformamide, in the presence of an excess of base, preferably an organic base, such as triethylamine, at a suitable temperature, for example at room temperature, for a time ranging from 1 to 40 hours and preferably between 4 and 18 hours, so as to form the thiazolyl ring and give the compound of the formula (III):
- BOC ferf-butoxy- carbonyl
- T, R 4 and R 5 are as defined above, which compound of the formula (III) is then saponified with a base, of alkali metal or alkaline-earth metal hydroxide type, for example sodium hydroxide, in polar medium, for instance tetrahydrofuran and/or water, especially a 2:1 tetra- hydrofuran/water mixture, at room temperature, for a time ranging from 1 to 12 hours, so as to form the salt of the formula (IV): in which T, R 4 and R 5 are as defined above, and M + represents the alkali metal or alkaline-earth metal cation derived from the base that is useful for the saponifica- tion reaction, which compound of the formula (IV) is next hydrolysed and then/or esteri- fied to a compound of the formula (V1):
- a base of alkali metal or alkaline-earth metal hydroxide type, for example sodium hydroxide, in polar medium, for instance tetrahydrofuran and/
- R 2 , R 3 , R 4 , R 5 and T are as defined above, via the action of an amine of the formula HNR 2 R 3 , generally in equimolar proportions, in the presence of a base, preferably an organic base, such as diisopropylethylamine (DIPEA), and a catalyst, for example O-benzotriazol-1-yl- N,N,N',N'-tetraethyluronium hexafluorophosphate (HBTU), in a polar aprotic solvent, such as dimethylformamide, at room temperature, for a time that can range from 1 to 50 hours and generally from 4 to 20 hours, the compounds of the formulae (V1 ) and (V2) together forming the compound of the formula (V):
- a base preferably an organic base, such as diisopropylethylamine (DIPEA)
- DIPEA diisopropylethylamine
- HBTU O-benzo
- X represents a halogen atom, preferably chlorine, R 1 , Y and Z being as defined above
- a base preferably an organic base, such as diisopropylethylamine (DIPEA), and a catalyst, for example O-benzotriazol-1-yl- N,N,N',N'-tetraethyluronium hexafluorophosphate (HBTU), in a polar aprotic sol- vent, such as dimethylformamide, at room temperature, for a time that can range from 1 to 50 hours and generally from 4 to 20 hours, to give the compound of the formula (I) as defined above.
- DIPEA diisopropylethylamine
- HBTU O-benzotriazol-1-yl- N,N,N',N'-tetraethyluronium hexafluorophosphate
- a polar aprotic sol- vent such as dimethylformamide
- the compounds of the formula (I) can also be prepared by reacting a compound of the formula chosen from:
- the present invention also relates to pharmaceutical compositions comprising an effective pharmaceutical amount of a compound of the formula (I), as defined above, in combination with one or more pharmaceutically acceptable vehicles.
- compositions can be administered orally in the form of immediate-release or controlled-release tablets, gel capsules or granules, intravenously in the form of an injectable solution, transdermally in the form of an adhesive transdermal device, or locally in the form of a solution, cream or gel.
- a solid composition for oral administration is prepared by adding to the active principle a filler and, where appropriate, a binder, a disintegrating agent, a lubricant, a colorant or a flavour enhancer, and by forming the mixture into a tablet, a coated tablet, a granule, a powder or a capsule.
- fillers include lactose, corn starch, sucrose, glucose, sorbitol, crystalline cellulose and silicon dioxide
- binders include poly(vinyl alcohol), poly(vinyl ether), ethylcellulose, methylcellulose, acacia, gum tragacanth, gelatin, Shellac, hydroxypropylcellulose, hydroxypropylmethyl- cellulose, calcium citrate, dextrin and pectin.
- lubricants include magnesium stearate, talc, polyethylene glycol, silica and hardened plant oils.
- the colorant can be any colorant permitted for use in medicaments.
- flavour enhancers include cocoa powder, mint in herb form, aromatic powder, mint in oil form, borneol and cinnamon powder. It should be understood that the tablet or granule may be suitably coated with sugar, gelatin or the like.
- An injectable form comprising the compound of the present invention as active principle is prepared, where appropriate, by mixing the said compound with a pH regulator, a buffer agent, a suspension agent, a solubilizer, a stabilizer, a tonicity agent and/or a preserving agent, and by converting the mixture into a form for intravenous, subcutaneous or intramuscular injection, according to a conventional process. Where appropriate, the injectable form obtained can be lyophilized via a conventional process.
- suspension agents include methylcellulose, polysorbate 80, hydroxyethylcellulose, acacia, powdered gum tragacanth, sodium carboxy- methylcellulose and polyethoxylated sorbitan monolaurate.
- solubilizers include castor oil solidified with polyoxy- ethylene, polysorbate 80, nicotinamide, polyethoxylated sorbitan monolaurate and the ethyl ester of castor oil fatty acid.
- the stabilizer includes sodium sulfite, sodium metasulfite and ether
- the preserving agent includes methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate, sorbic acid, phenol, cresol and chlorocresol.
- a subject of the present invention is also a use of a compound of the formula (I) of the invention for the preparation of a medicament for the treatment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia associated with diabetes, and also for the prevention of and treating obesity.
- Example 1 2-[1-(6-Methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4- yl]thiazol-4-carbonyl[N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl)]amide
- Step b) terf-Butyl 4-(4-carboxythiazol-2-yl)piperidine-1 -carboxylate tett-Butyl 4-(4-ethoxycarbonylthiazol-2-yl)piperidine-1 -carboxylate
- Step c) fe/f-Butyl 4- ⁇ 4-fethyl(1-methyl-2-oxo-2-phenylethyl)carbamovnthiazol-2-yl)- piperidine-1 -carboxylate tetf-Butyl 4-(4-carboxythiazol-2-yl)piperidine-1 -carboxylate (6.5 mmol; 2.03 g) is dissolved in 40 ml of anhydrous dimethylformamide and placed under an inert atmosphere, and 2-(ethylamino)propiophenone hydrochloride (1 eq.; 6.5 mmol; 1.39 g), HBTU (1 eq.; 6.5 mmol; 2.47 g) and N-ethyldiisopropylamine (3.5 eq.; 22.75 mmol; 3.97 ml) are then added.
- 2-(ethylamino)propiophenone hydrochloride (1 eq.;
- the reaction medium is stirred at room temperature overnight.
- the reaction medium is evaporated to dryness and then taken up in dichloromethane and washed with saturated potassium carbonate (K 2 CO 3 ) solution, citric acid solution and water (twice).
- K 2 CO 3 saturated potassium carbonate
- the organic phase is dried over sodium sulfate and then evaporated to dryness.
- Example 2 1 -(4- ⁇ 4-(1 -morpholin-4-yl)methanoyl]thiazol-2-yl ⁇ piperid-1 -yl)-1 -(4'- trifluoromethylbiphenyl-2-yl)methanone
- Step a) 1 - ⁇ '-(trifluoromethyl )-1 ,1 '-biphenyl-2-yl1carbonyl)piperidine-4-carbox- amide 4'-(Trifluoromethyl)-2-biphenylcarboxylic acid (20.5 g; 77 mmol) is dissolved in 340 ml of dimethylformamide and 200 ml of dichloromethane. The reaction medium is placed at 0°C and oxalyl chloride (1.8 eq.; 138.6 mmol; 12 ml) is added. The reaction medium is stirred at room temperature for 3 hours and then evaporated to dryness.
- the crude product is taken up in 270 ml of dichloro- methane, followed by addition of a solution of isonipecotamide (0.97 eq.; 74.7 mmol; 9.57 g) and triethylamine (2.7 eq.; 207.9 mmol; 29 ml) in 270 ml of dichloromethane, placed at 0°C.
- the mixture is allowed to warm to room temperature over 12 hours, saturated aqueous sodium hydrogen carbonate solution is then added (in a 1/1 proportion) and the resulting mixture is stirred for 30 minutes.
- the organic phase is washed with 1M sodium hydroxide solution and then with water, dried over sodium sulfate and evaporated to dryness.
- the crude product is dispersed in diisopropyl ether and then filtered off and dried to give 23.09 g of coupling product. Yield: 79.6 %.
- Step c) Ethyl 2-(1-(r4'-(trifluoromethvO-1.1'-biphenyl-2-ylIcarbonyl)piperidine-4-ylM.3-thia- zole-4-carboxylate 1 - ⁇ [4'-(Trifluoromethyl)-1 ,1 '-biphenyl-2-yl]carbonyl ⁇ piperidine-4-carbothio- amide (10.5 g; 26.75 mmol) is dissolved in 100 ml of dimethylformamide and placed at 0°C.
- the title compound was obtained according to a procedure similar to that used for the preparation of tert-butyl 4-(4-carboxythiazol-2-yl)piperidine-1 -carboxylate. Yield: quantitative.
- the procedure below shows a synthetic route that can be used for the preparation of an amine of the formula H-a2': Preparation of 2-ethylamino-1-pyrid-2-ylpropan-1 -one in the form of the acid salt with bis-trifluoroacetic acid Step a) Methyl 2-(2-nitrobenzenesulfonylamino)propionate DL-Alanine methyl ester hydrochloride (13.96 g; 0.1 mol) is dissolved in 800 ml of dichloromethane and placed at 0°C.
- Triethylamine (2.3 eq.; 230 mmol; 32 ml) is added dropwise, along with portionwise addition of 2-nitrobenzene- sulfonyl chloride (1 eq.; 100 mmol; 22.16 g), and the reaction medium is allowed to return to room temperature overnight. The reaction medium is washed with water and then dried over sodium sulfate, filtered through silica and evaporated to dryness to give 25.3 g of solid corresponding to the title compound. Yield: 88 %.
- Step b) Methyl 2-[ethyl(2-nitrobenzenesulfonyl)amino1propionate Methyl 2-(2-nitrobenzenesulfonylamino)propionate (17 g; 59 mmol) is dissolved in 600 ml of dimethylformamide, and caesium carbonate (1.5 eq.; 88 mmol; 28.6 g) is then added. The reaction medium is stirred for 30 minutes at room temperature, followed by dropwise addition of ethyl bromide (4 eq.; 236 mmol; 17.6 ml) and the resulting mixture is stirred overnight at room temperature.
- the reaction medium is evaporated to dryness, taken up in dichloromethane, filtered and evaporated to dryness.
- the crude product is chromatographed on silica (eluting with dichloromethane) to give 17.1 g of the expected product. Yield: 92 %.
- the reaction medium is stirred overnight at room temperature.
- the crude product is evaporated to dryness and then taken up in ether.
- the organic phase is acidified with 1 N hydrochloric acid and then washed with water.
- the aqueous phases are combined and then washed with ether and basified with potassium carbonate.
- the basic aqueous phase is extracted with ether three times.
- the three ether phases are washed with water and then with saturated aqueous sodium chloride solution, dried over sodium sulfate and evaporated to dryness to give 1.04 g of the expected product. Yield: 31 %.
- Step d) Methyl 2-(terf-butoxycarbonylethylamino)propionate Methyl 2-ethylaminopropionate (0.96 g; 7.3 mmol) is dissolved in 10 ml of dichloromethane, and triethylamine (1 eq.; 7.3 mmol; 1 ml) and Boc-O-Boc (1.1 eq.; 8 mmol; 1.75 g) are added. The reaction medium is stirred for 12 hours at room temperature and then washed with water, dried over sodium sulfate and evaporated to dryness to give 1.28 g of the expected product. Yield: 76 %.
- Step e bis Alternative route: DL-2-Bromopropionic acid (76.5 g; 0.5 mol) is dissolved in 250 ml of water and 70% ethylamine (4.7 eq.; 2.3 mol;. 150 g) is added dropwise. The reaction medium is stirred at room temperature for 12 hours and then evaporated to dry- ness and taken up in 400 ml of water comprising 40 g of sodium hydroxide
- the reaction medium is again evaporated to dryness.
- the crude product is dissolved in 500 ml of water and 250 ml of dioxane.
- the reaction medium is placed at 0°C and di(terf-butyl) carbonate (1.1 eq.; 0.55 mol; 120 g) dissolved in 200 ml of dioxane is added dropwise.
- the pH is maintained at 10 by adding sodium hydroxide.
- the reaction medium is stirred at room temperature for 24 hours and then filtered.
- the filtrate is concentrated and then taken up in 700 ml of water and acidified to pH 2-3 with citric acid.
- the precipitate is filtered off and dried (108.6 g). Yield: 62 %.
- Step f) Dimethyl ethyl ethylfl-fmethoxymethylcarbamovDethyllcarbamate 2-(terf-Butoxycarbonylethylamino)propionic acid (40 mmol; 873 mg) is dissolved in 5 ml of dimethylformamide, and N,O-dimethylhydroxylamine hydro- chloride (1.25 eq.; 5.0 mmol; 490 mg), HOBT (1.25 eq.; 5.0 mmol; 676 mg), triethylamine (1.25 eq.; 5.0 mmol; 0.7 ml) and EDC (1.25 eq.; 5.0 mmol; 960 mg) are added.
- the reaction medium is stirred for 12 hours and then evaporated to dryness.
- the crude product is extracted with ether, washed successively, twice with aqueous 4% citric acid solution, twice with aqueous 4% sodium hydrogen sul- fite solution, with water and then with saturated sodium chloride solution.
- Step Q tet -Butyl ethyl(1-methyl-2-oxo-2-pyrid-2-ylethyl)carbamate
- 2-Bromopyridine 7.0 mmol; 667 ⁇ L
- a 1.6M solution of n-butyllithium in hexane (1 eq.; 7.0 mmol; 4.375 ml).
- the reaction medium is stirred for 30 minutes and dimethyl ethyl ethyl[1-(methoxymethyl- carbamoyl)ethyl]carbamate (1 eq.; 7.0 mmol; 1.822 g) dissolved in 20 ml of anhydrous tetrahydrofuran is added dropwise.
- the reaction medium is stirred at -100°C for 1 hour 30 minutes.
- the reaction medium is then removed from the ice bath, 200 ml of saturated aqueous sodium chloride solution are added and the mixture is then extracted with ether.
- MTP MTP was tested by using the following operating protocol.
- the inhibition of MTP activity with a compound can be quantified by observing the inhibition of the transfer of a labelled triglyceride, from a donor particle to an acceptor particle, in the presence of MTP.
- the procedure for the prepa- ration of MTP is based on the method by Wetterau and Zilversmit (Biochem. Biophys. Ada (1986) 875, 610). A few grams of golden hamster liver are taken and then rinsed several times in a 250 mM sucrose solution at 0°C. All the following steps proceed at +4°C.
- a homogenate at a concentration of 50% in 250 mM sucrose is prepared using a Teflon mill and then centrifuged for 10 minutes at 10 000 ⁇ g at +4°C. The supernatant is then centrifuged at 105 OOOxg for 75 minutes at +4°C. The supernatant is discarded and the microsomal pellet is taken up in 3 ml (per g of starting liver) of Tris/HCI 150 mM pH 8.0. 1-ml aliquot fractions are stored at -80°C until the time of use.
- the MTP is stored at +4°C, is stable for at least 30 days and is used in unmodified form in the test.
- the donor particles liposomes
- the donor particles are prepared from 208 ⁇ L of L-phosphatidylcholine at a concentration of 10 mg/ml in chloroform, and 480 ⁇ L of [3H]-triolein at a concentration of 0.5 mCi/ml in toluene. After stirring, the solution is evaporated under nitrogen, taken up in 6 ml of Tris/HCI 50 mM, KCl 50 mM, MgCI 2 5 mM pH 7.4 buffer and incubated in an ultrasound bath for 30 minutes at room temperature.
- the liposomes are stored at +4°C and sonicated again for 10 minutes before each use.
- the acceptor particles are biotinylated low density lipoproteins (LDL-biot). These particles are supplied by the company Amersham.
- the reaction mixture is prepared in untreated ! well white plates (Corning Costar) by addition, in the following order, of: 5 ⁇ L of HEPES 50 mM, NaCl 150 mM, BSA 0.1% (w/v), 0.05% sodium azide (w/v), pH 7.4 buffer; 5 ⁇ L of liposomes; 5 ⁇ L of LDL-biot; 5 ⁇ L of test products in DMSO; 5 ⁇ L of MTP.
- the activity of a compound according to the invention can be evaluated by measuring the inhibition of apo B secretion in HepG2 cells.
- the HepG2 cells (ECACC - No. 85011430) are used as model in the study of the in vitro hepatic secretion of lipoproteins (Dixon J. and Ginsberg H., J. Lipid. Res., 1993, 34,167-179).
- the HepG2 cells are cultured in Dulbecco's modified Eagle's medium comprising 10% foetal calf serum (DMEM and FBS - Gibco) in 96-well plates under an atmosphere of 5% carbon dioxide for 24 hours (about 70% confluence).
- test compounds are dissolved at a concentration of 2 or 10 mM in dimethyl sulfoxide (DMSO). Serial dilutions (1 :3.16) are made in DMSO and are added (1:200 - Robot Multimek Beckman) to the growth medium (200 ⁇ L) and then finally incubated for 24 hours in the various wells containing the HepG2 cells.
- DMSO dimethyl sulfoxide
- the 24-hour culture supernatant diluted to 1 :5 phosphate-buffered saline: PBS comprising 1 % bovine serum albumin
- the results are expressed in terms of IC 5 o, i.e. the concentration that produces a 50% inhibition of apo B secretion in the HepG2 cells.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05013521A MXPA05013521A (en) | 2003-06-25 | 2004-06-02 | Thiazolylpiperidine derivatives as mtp inhibitors. |
DE602004020223T DE602004020223D1 (en) | 2003-06-25 | 2004-06-02 | THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS |
CA2531011A CA2531011C (en) | 2003-06-25 | 2004-06-02 | Thiazolylpiperidine derivatives as mtp inhibitors |
BRPI0411721-2A BRPI0411721A (en) | 2003-06-25 | 2004-06-02 | thiazolylpiperidine derivatives as mtp inhibitors |
JP2006515818A JP4629666B2 (en) | 2003-06-25 | 2004-06-02 | Thiazolylpiperidine derivatives as mtp inhibitors |
US10/561,989 US7674803B2 (en) | 2003-06-25 | 2004-06-02 | Thiazolypiperidine derivatives as MTP inhibitors |
AU2004253649A AU2004253649B2 (en) | 2003-06-25 | 2004-06-02 | Thiazolylpiperidine derivatives as MTP inhibitors |
EP04735742A EP1636218B1 (en) | 2003-06-25 | 2004-06-02 | Thiazolylpiperidine derivatives as mtp inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR03/07670 | 2003-06-25 | ||
FR0307670A FR2856685B1 (en) | 2003-06-25 | 2003-06-25 | THIAZOLYLPIPERIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005003128A1 true WO2005003128A1 (en) | 2005-01-13 |
Family
ID=33515396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/005931 WO2005003128A1 (en) | 2003-06-25 | 2004-06-02 | Thiazolylpiperidine derivatives as mtp inhibitors |
Country Status (18)
Country | Link |
---|---|
US (1) | US7674803B2 (en) |
EP (1) | EP1636218B1 (en) |
JP (1) | JP4629666B2 (en) |
KR (1) | KR20060024812A (en) |
CN (1) | CN1809560A (en) |
AR (1) | AR044909A1 (en) |
AT (1) | ATE426599T1 (en) |
AU (1) | AU2004253649B2 (en) |
BR (1) | BRPI0411721A (en) |
CA (1) | CA2531011C (en) |
DE (1) | DE602004020223D1 (en) |
ES (1) | ES2323463T3 (en) |
FR (1) | FR2856685B1 (en) |
MX (1) | MXPA05013521A (en) |
RU (1) | RU2006101890A (en) |
TW (1) | TW200518751A (en) |
WO (1) | WO2005003128A1 (en) |
ZA (1) | ZA200600690B (en) |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1637529A1 (en) * | 2004-09-20 | 2006-03-22 | 4Sc Ag | Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof |
WO2006032322A1 (en) * | 2004-09-20 | 2006-03-30 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
WO2007014290A2 (en) | 2005-07-26 | 2007-02-01 | E. I. Du Pont De Nemours And Company | Fungicidal carboxamides |
WO2007016979A2 (en) * | 2005-07-29 | 2007-02-15 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
WO2007020213A2 (en) * | 2005-08-18 | 2007-02-22 | F. Hoffmann-La Roche Ag | Thiazolyl piperidine derivatives useful as h3 receptor modulators |
EP1832586A1 (en) * | 2006-03-10 | 2007-09-12 | Oridis Biomed Forschungs- und Entwicklungs GmbH | Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas |
EP1834954A1 (en) * | 2006-03-15 | 2007-09-19 | 4Sc Ag | Thiazoles as NF-kB Inhibitors (proteasome inhibitors) |
WO2008013622A2 (en) * | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
WO2008091580A2 (en) | 2007-01-25 | 2008-07-31 | E. I. Du Pont De Nemours And Company | Fungicidal amides |
WO2009058728A1 (en) * | 2007-10-29 | 2009-05-07 | Schering Corporation | Thiazole derivatives as protein kinase inhibitors |
WO2009046842A3 (en) * | 2007-10-05 | 2009-06-25 | Merck Patent Gmbh | Thiazol derivatives for treating cancer |
JP2009529555A (en) * | 2006-03-15 | 2009-08-20 | 4エスツェー アクチェンゲゼルシャフト | Novel heterocyclic NF-κB inhibitor |
US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
JP2010508274A (en) * | 2006-10-31 | 2010-03-18 | シェーリング コーポレイション | Anilinopiperazine derivatives and methods using anilinopiperazine derivatives |
US20100130465A1 (en) * | 2006-10-31 | 2010-05-27 | Shipps Jr Gerald W | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
US20100292275A1 (en) * | 2008-01-25 | 2010-11-18 | E.I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
WO2011051243A1 (en) | 2009-10-29 | 2011-05-05 | Bayer Cropscience Ag | Active compound combinations |
WO2011051244A1 (en) | 2009-10-30 | 2011-05-05 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives |
US8093389B2 (en) | 2007-01-12 | 2012-01-10 | Merck Sharp & Dohme Corp. | Substituted spirochromanone derivatives |
US8101623B2 (en) | 2007-10-11 | 2012-01-24 | Astrazeneca Ab | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor |
US8163746B2 (en) * | 2006-04-19 | 2012-04-24 | Astellas Pharma Inc. | Azolecarboxamide derivative |
WO2012112743A1 (en) * | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
US20120245204A1 (en) * | 2011-02-01 | 2012-09-27 | Bayer Cropscience Ag | Unknown |
US8304547B2 (en) | 2007-10-24 | 2012-11-06 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
US8449898B2 (en) | 2007-10-23 | 2013-05-28 | E I Du Pont De Nemours And Company | Fungicidal mixtures |
US8546407B2 (en) | 2004-10-25 | 2013-10-01 | Astex Therapeutics Limited | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors |
CN103347879A (en) * | 2011-02-10 | 2013-10-09 | 先正达参股股份有限公司 | Microbiocidal pyrazole derivatives |
US8569509B2 (en) | 2008-04-30 | 2013-10-29 | Bayer Intellectual Property Gmbh | Thiazole-4-carboxylic acid esters and thioesters as plant protection agents |
US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
US8618137B2 (en) | 2008-12-02 | 2013-12-31 | E I Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
US8796293B2 (en) | 2006-04-25 | 2014-08-05 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
US8916565B2 (en) | 2011-02-02 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
WO2015018027A1 (en) * | 2013-08-08 | 2015-02-12 | Merck Sharp & Dohme Corp. | Thiazole orexin receptor antagonists |
US9090604B2 (en) | 2006-07-27 | 2015-07-28 | E I Du Pont De Nemours And Company | Fungicidal azocyclic amides |
WO2016086357A1 (en) * | 2014-12-02 | 2016-06-09 | Merck Sharp & Dohme Corp. | Methyl oxazole orexin receptor antagonists |
US9402847B2 (en) | 2011-04-01 | 2016-08-02 | Astrazeneca Ab | Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide |
US9487525B2 (en) | 2012-04-17 | 2016-11-08 | Astrazeneca Ab | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide |
US9737540B2 (en) | 2011-11-30 | 2017-08-22 | Astrazeneca Ab | Combination treatment of cancer |
EP3573619A4 (en) * | 2017-01-27 | 2020-10-28 | SignalRX Pharmaceuticals, Inc. | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2865733B1 (en) * | 2004-02-04 | 2007-10-12 | Merck Sante Sas | THIAZOLYLIMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND MEDICINE APPLICATIONS THEREOF |
US20100267717A1 (en) * | 2005-07-29 | 2010-10-21 | 4Sc Ag | Novel Heterocyclic NF-kB Inhibitors |
WO2007115805A2 (en) * | 2006-04-05 | 2007-10-18 | European Molecular Biology Laboratory (Embl) | Aurora kinase inhibitors |
BRPI0920767B1 (en) * | 2008-10-01 | 2018-07-17 | Bayer Intellectual Property Gmbh | heterocyclyl substituted thiazols as protective agents for cultivation, their uses and their preparation processes, compositions and their preparation process, and method for combating phytopathogenic harmful fungi |
WO2010101246A1 (en) * | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
EP2272846A1 (en) * | 2009-06-23 | 2011-01-12 | Bayer CropScience AG | Thiazolylpiperidine derivatives as fungicide |
EA021058B1 (en) * | 2009-08-12 | 2015-03-31 | Зингента Партисипейшнс Аг | Heterocycles having fungicidal activity |
CN102666532A (en) * | 2009-12-22 | 2012-09-12 | 先正达参股股份有限公司 | Pyrazole derivatives |
KR20130100903A (en) * | 2010-04-28 | 2013-09-12 | 바이엘 크롭사이언스 아게 | Ketoheteroarylpiperidine and ketoheteroarylpiperazine derivatives as fungicides |
US8815775B2 (en) * | 2010-05-18 | 2014-08-26 | Bayer Cropscience Ag | Bis(difluoromethyl)pyrazoles as fungicides |
US11312685B2 (en) * | 2017-04-28 | 2022-04-26 | Texas Heart Institute | Targeting nanoparticles |
CN111196805A (en) * | 2018-11-17 | 2020-05-26 | 曲阜德禄生物科技有限公司 | Synthesis method and application of piperidyl thiazole formamide compound |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2816940A1 (en) * | 2000-11-23 | 2002-05-24 | Lipha | New 4-(biphenyl carbonylamino) piperidine derivatives are microsomal triglyceride transfer protein and apoprotein B secretion inhibitors used for treating e.g. hypercholesterolemia and obesity |
WO2003047575A1 (en) * | 2001-12-04 | 2003-06-12 | Glaxo Group Limited | Therapeutic benzamide derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997015567A1 (en) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-membered heterocycles, pharmaceutical agents containing said compounds and the use thereof and methods of producing them |
US5965537A (en) * | 1997-03-10 | 1999-10-12 | Basf Aktiengesellschaft | Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus |
AU2001263827B2 (en) * | 2000-04-04 | 2004-06-17 | Smithkline Beecham Plc | 2-hydroxy-mutilin carbamate derivatives for antibacterial use |
GB0230162D0 (en) * | 2002-12-24 | 2003-02-05 | Metris Therapeutics Ltd | Compounds useful in inhibiting angiogenesis |
-
2003
- 2003-06-25 FR FR0307670A patent/FR2856685B1/en not_active Expired - Fee Related
-
2004
- 2004-06-02 ES ES04735742T patent/ES2323463T3/en not_active Expired - Lifetime
- 2004-06-02 US US10/561,989 patent/US7674803B2/en not_active Expired - Fee Related
- 2004-06-02 AT AT04735742T patent/ATE426599T1/en not_active IP Right Cessation
- 2004-06-02 AU AU2004253649A patent/AU2004253649B2/en not_active Ceased
- 2004-06-02 EP EP04735742A patent/EP1636218B1/en not_active Expired - Lifetime
- 2004-06-02 CA CA2531011A patent/CA2531011C/en not_active Expired - Fee Related
- 2004-06-02 KR KR1020057024663A patent/KR20060024812A/en not_active Application Discontinuation
- 2004-06-02 BR BRPI0411721-2A patent/BRPI0411721A/en not_active IP Right Cessation
- 2004-06-02 RU RU2006101890/04A patent/RU2006101890A/en unknown
- 2004-06-02 JP JP2006515818A patent/JP4629666B2/en not_active Expired - Fee Related
- 2004-06-02 MX MXPA05013521A patent/MXPA05013521A/en unknown
- 2004-06-02 DE DE602004020223T patent/DE602004020223D1/en not_active Expired - Lifetime
- 2004-06-02 WO PCT/EP2004/005931 patent/WO2005003128A1/en active Application Filing
- 2004-06-02 CN CNA2004800157394A patent/CN1809560A/en active Pending
- 2004-06-21 TW TW093117985A patent/TW200518751A/en unknown
- 2004-06-25 AR ARP040102230A patent/AR044909A1/en unknown
-
2006
- 2006-01-24 ZA ZA200600690A patent/ZA200600690B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2816940A1 (en) * | 2000-11-23 | 2002-05-24 | Lipha | New 4-(biphenyl carbonylamino) piperidine derivatives are microsomal triglyceride transfer protein and apoprotein B secretion inhibitors used for treating e.g. hypercholesterolemia and obesity |
WO2003047575A1 (en) * | 2001-12-04 | 2003-06-12 | Glaxo Group Limited | Therapeutic benzamide derivatives |
Cited By (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8106048B2 (en) | 2004-09-20 | 2012-01-31 | 4Sc Ag | Heterocyclic NF-κB inhibitors |
WO2006032322A1 (en) * | 2004-09-20 | 2006-03-30 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
EA012607B1 (en) * | 2004-09-20 | 2009-10-30 | 4Сц Аг | NOVEL HETEROCYCLIC NF-kB INHIBITORS |
US7812041B2 (en) | 2004-09-20 | 2010-10-12 | 4Sc Ag | Heterocyclic NF-κB inhibitors |
EP1637529A1 (en) * | 2004-09-20 | 2006-03-22 | 4Sc Ag | Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof |
EP2343293A1 (en) * | 2004-09-20 | 2011-07-13 | 4Sc Ag | Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of t-cell proliferation and uses thereof |
US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
US8546407B2 (en) | 2004-10-25 | 2013-10-01 | Astex Therapeutics Limited | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors |
US8586611B2 (en) | 2005-07-26 | 2013-11-19 | E. I. Du Pont De Nemours And Company | Fungicidal carboxamides |
WO2007014290A3 (en) * | 2005-07-26 | 2007-06-07 | Du Pont | Fungicidal carboxamides |
KR101332900B1 (en) | 2005-07-26 | 2013-11-27 | 이 아이 듀폰 디 네모아 앤드 캄파니 | Fungicidal carboxamides |
WO2007014290A2 (en) | 2005-07-26 | 2007-02-01 | E. I. Du Pont De Nemours And Company | Fungicidal carboxamides |
JP2009502948A (en) * | 2005-07-26 | 2009-01-29 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Bactericidal carboxamide |
JP2009502816A (en) * | 2005-07-29 | 2009-01-29 | 4エスツェー アクチェンゲゼルシャフト | Novel heterocyclic NF-κB inhibitor |
EA016300B1 (en) * | 2005-07-29 | 2012-04-30 | 4ЭсЦэ АГ | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
WO2007016979A2 (en) * | 2005-07-29 | 2007-02-15 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
WO2007016979A3 (en) * | 2005-07-29 | 2007-08-02 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
US7786143B2 (en) | 2005-08-18 | 2010-08-31 | Hoffman-La Roche Inc. | Thiazolyl piperidine derivatives |
KR100962827B1 (en) * | 2005-08-18 | 2010-06-10 | 에프. 호프만-라 로슈 아게 | Thiazolyl piperidine derivatives useful as h3 receptor modulators |
WO2007020213A3 (en) * | 2005-08-18 | 2007-04-12 | Hoffmann La Roche | Thiazolyl piperidine derivatives useful as h3 receptor modulators |
WO2007020213A2 (en) * | 2005-08-18 | 2007-02-22 | F. Hoffmann-La Roche Ag | Thiazolyl piperidine derivatives useful as h3 receptor modulators |
EP1832586A1 (en) * | 2006-03-10 | 2007-09-12 | Oridis Biomed Forschungs- und Entwicklungs GmbH | Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas |
JP2009529555A (en) * | 2006-03-15 | 2009-08-20 | 4エスツェー アクチェンゲゼルシャフト | Novel heterocyclic NF-κB inhibitor |
JP2009529556A (en) * | 2006-03-15 | 2009-08-20 | 4エスツェー アクチェンゲゼルシャフト | Thiazole as an NF-κB inhibitor (proteasome inhibitor) |
EP1834954A1 (en) * | 2006-03-15 | 2007-09-19 | 4Sc Ag | Thiazoles as NF-kB Inhibitors (proteasome inhibitors) |
WO2007104558A1 (en) * | 2006-03-15 | 2007-09-20 | 4Sc Ag | Thiazoles as nf-kb inhibitors (proteasome inhibitors) |
US8163746B2 (en) * | 2006-04-19 | 2012-04-24 | Astellas Pharma Inc. | Azolecarboxamide derivative |
JP5182088B2 (en) * | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | Azole carboxamide derivatives |
US8796293B2 (en) | 2006-04-25 | 2014-08-05 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
WO2008013622A2 (en) * | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
EP2712616A1 (en) * | 2006-07-27 | 2014-04-02 | E. I. du Pont de Nemours and Company | N-carbonyl, 4-heterocyclyl substituted azocyclic compounds as fungicides |
US8642634B2 (en) | 2006-07-27 | 2014-02-04 | E I Du Pont De Nemours And Company | Fungicidal azocyclic amides |
CN101888843B (en) * | 2006-07-27 | 2015-04-15 | 杜邦公司 | Fungicidal azocyclic amides |
US9090604B2 (en) | 2006-07-27 | 2015-07-28 | E I Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US9604962B2 (en) | 2006-07-27 | 2017-03-28 | E I Du Pont De Nemours And Company | Fungicidal azocyclic amides |
CN106986866A (en) * | 2006-07-27 | 2017-07-28 | 杜邦公司 | Fungicidal azocyclic amides |
EP3239137A1 (en) | 2006-07-27 | 2017-11-01 | E. I. du Pont de Nemours and Company | (5r)-4,5-dihydro-isoxazole derivatives as well as 1-(2-chloroacetyl)-4-piperidine-carbonitrile and -carboxamide derivatives as intermediates in the preparation of e.g. 4-[4-[(5r)-4,5-dihydro-isoxazol-3-yl]-thiazol-2-yl]-piperidine derivatives as fungicides for crop protection |
CN101888843A (en) * | 2006-07-27 | 2010-11-17 | 杜邦公司 | Fungicidal azocyclic amides |
EP3239145A1 (en) | 2006-07-27 | 2017-11-01 | E. I. du Pont de Nemours and Company | 1-[2-[3,5-substituted-1h-pyrazol-1-yl]acetyl]-4-piperidine-carbonitrile and -carbothiamide derivatives as intermediates in the preparation of fungicides for crop protection |
US9920030B2 (en) | 2006-07-27 | 2018-03-20 | E I Du Pont De Nemours And Company | Fungicidal azocyclic amides |
CN106986866B (en) * | 2006-07-27 | 2020-03-03 | 杜邦公司 | Fungicidal azacyclic amides |
WO2008013925A3 (en) * | 2006-07-27 | 2008-04-03 | Du Pont | Fungicidal azocyclic amides |
WO2008013622A3 (en) * | 2006-07-27 | 2008-03-27 | Du Pont | Fungicidal azocyclic amides |
WO2008013925A2 (en) * | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US20120328691A1 (en) * | 2006-10-31 | 2012-12-27 | Shipps Jr Gerald W | Anilinopiperazine derivatives and methods of use thereof |
US20100130465A1 (en) * | 2006-10-31 | 2010-05-27 | Shipps Jr Gerald W | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
JP2010508274A (en) * | 2006-10-31 | 2010-03-18 | シェーリング コーポレイション | Anilinopiperazine derivatives and methods using anilinopiperazine derivatives |
US8318735B2 (en) * | 2006-10-31 | 2012-11-27 | Merck Sharp & Dohme Corp. | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
US9206142B2 (en) * | 2006-10-31 | 2015-12-08 | Merck Sharp & Dohme Corp. | Anilinopiperazine derivatives and methods of use thereof |
JP2010511624A (en) * | 2006-12-01 | 2010-04-15 | ブリストル−マイヤーズ スクイブ カンパニー | N-((3-Benzyl) -2,2- (bis-phenyl) -propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular disease |
US9102599B2 (en) | 2006-12-01 | 2015-08-11 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
WO2008070496A3 (en) * | 2006-12-01 | 2008-09-18 | Bristol Myers Squibb Co | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
CN101663262A (en) * | 2006-12-01 | 2010-03-03 | 百时美施贵宝公司 | The N-as the CETP inhibitor (3-benzyl)-2 that is used for the treatment of atherosclerosis and cardiovascular disorder, 2-(phenylbenzene)-the third-1 sulfonamide derivatives |
US8093389B2 (en) | 2007-01-12 | 2012-01-10 | Merck Sharp & Dohme Corp. | Substituted spirochromanone derivatives |
WO2008091580A2 (en) | 2007-01-25 | 2008-07-31 | E. I. Du Pont De Nemours And Company | Fungicidal amides |
US8420673B2 (en) | 2007-01-25 | 2013-04-16 | E I Du Pont De Nemours And Company | Fungicidal amides |
WO2008091580A3 (en) * | 2007-01-25 | 2008-09-12 | Du Pont | Fungicidal amides |
JP2010516765A (en) * | 2007-01-25 | 2010-05-20 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Bactericidal amide |
CN101622245A (en) * | 2007-01-25 | 2010-01-06 | 纳幕尔杜邦公司 | Fungicidal amides |
WO2009046842A3 (en) * | 2007-10-05 | 2009-06-25 | Merck Patent Gmbh | Thiazol derivatives for treating cancer |
AU2008310068B2 (en) * | 2007-10-05 | 2014-05-01 | Merck Patent Gmbh | Thiazol derivatives for treating cancer |
US8557824B2 (en) | 2007-10-05 | 2013-10-15 | Merck Patent Gmbh | Thiazole derivatives |
US20100240676A1 (en) * | 2007-10-05 | 2010-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Thiazole derivatives |
US8101623B2 (en) | 2007-10-11 | 2012-01-24 | Astrazeneca Ab | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor |
US9492453B2 (en) | 2007-10-11 | 2016-11-15 | Astrazeneca Ab | Protein kinase B inhibitors |
US10059714B2 (en) | 2007-10-11 | 2018-08-28 | Astrazeneca Ab | Protein kinase B inhibitors |
US10654855B2 (en) | 2007-10-11 | 2020-05-19 | Astrazeneca Ab | Protein kinase B inhibitors |
US11236095B2 (en) | 2007-10-11 | 2022-02-01 | Astrazeneca Ab | Protein kinase B inhibitors |
US11760760B2 (en) | 2007-10-11 | 2023-09-19 | Astrazeneca Ab | Protein kinase B inhibitors |
US8449898B2 (en) | 2007-10-23 | 2013-05-28 | E I Du Pont De Nemours And Company | Fungicidal mixtures |
US8304547B2 (en) | 2007-10-24 | 2012-11-06 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
WO2009058728A1 (en) * | 2007-10-29 | 2009-05-07 | Schering Corporation | Thiazole derivatives as protein kinase inhibitors |
US20100292275A1 (en) * | 2008-01-25 | 2010-11-18 | E.I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
EP2402332A2 (en) | 2008-01-25 | 2012-01-04 | E.I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
US8349870B2 (en) | 2008-01-25 | 2013-01-08 | E I Du Pont De Nemours And Company | Fungicidal hetercyclic compounds |
US9029549B2 (en) | 2008-04-30 | 2015-05-12 | Bayer Intellectual Property Gmbh | Thiazol-4-carboxylic acid esters and thioesters as plant protection agents |
US8569509B2 (en) | 2008-04-30 | 2013-10-29 | Bayer Intellectual Property Gmbh | Thiazole-4-carboxylic acid esters and thioesters as plant protection agents |
US8618137B2 (en) | 2008-12-02 | 2013-12-31 | E I Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
WO2011051243A1 (en) | 2009-10-29 | 2011-05-05 | Bayer Cropscience Ag | Active compound combinations |
WO2011051244A1 (en) | 2009-10-30 | 2011-05-05 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives |
US8501781B2 (en) | 2009-10-30 | 2013-08-06 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives |
US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
US9204649B2 (en) | 2011-02-01 | 2015-12-08 | Bayer Intellectual Property Gmbh | Heteroarylpiperidine and- piperazine derivates as fungicides |
US20120245204A1 (en) * | 2011-02-01 | 2012-09-27 | Bayer Cropscience Ag | Unknown |
US8822693B2 (en) * | 2011-02-01 | 2014-09-02 | Bayer Cropscience Ag | Heteroarylpiperidine and-piperazine derivatives as fungicides |
US8916565B2 (en) | 2011-02-02 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
US9511067B2 (en) | 2011-02-02 | 2016-12-06 | Vertex Pharmaceuticals Incorporated | Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels |
CN103347879A (en) * | 2011-02-10 | 2013-10-09 | 先正达参股股份有限公司 | Microbiocidal pyrazole derivatives |
US10385070B2 (en) | 2011-02-18 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
JP2014508756A (en) * | 2011-02-18 | 2014-04-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | Chroman-spirocyclic piperidine amides as modulators of ion channels |
WO2012112743A1 (en) * | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
AU2012217616B2 (en) * | 2011-02-18 | 2017-03-02 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
US9181273B2 (en) | 2011-03-14 | 2015-11-10 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
US9402847B2 (en) | 2011-04-01 | 2016-08-02 | Astrazeneca Ab | Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide |
US9737540B2 (en) | 2011-11-30 | 2017-08-22 | Astrazeneca Ab | Combination treatment of cancer |
US10039766B2 (en) | 2012-04-17 | 2018-08-07 | Astrazeneca Ab | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide |
US9487525B2 (en) | 2012-04-17 | 2016-11-08 | Astrazeneca Ab | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide |
WO2015018027A1 (en) * | 2013-08-08 | 2015-02-12 | Merck Sharp & Dohme Corp. | Thiazole orexin receptor antagonists |
US9695163B2 (en) | 2013-08-08 | 2017-07-04 | Merck Sharp & Dohme Corp | Thiazole orexin receptor antagonists |
US9920038B2 (en) | 2014-12-02 | 2018-03-20 | Merck Sharp & Dohme Corp. | Methyl oxazole orexin receptor antagonists |
WO2016086357A1 (en) * | 2014-12-02 | 2016-06-09 | Merck Sharp & Dohme Corp. | Methyl oxazole orexin receptor antagonists |
EP3573619A4 (en) * | 2017-01-27 | 2020-10-28 | SignalRX Pharmaceuticals, Inc. | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors |
Also Published As
Publication number | Publication date |
---|---|
TW200518751A (en) | 2005-06-16 |
CA2531011A1 (en) | 2005-01-13 |
ATE426599T1 (en) | 2009-04-15 |
KR20060024812A (en) | 2006-03-17 |
EP1636218B1 (en) | 2009-03-25 |
DE602004020223D1 (en) | 2009-05-07 |
JP2007506651A (en) | 2007-03-22 |
RU2006101890A (en) | 2007-07-27 |
ES2323463T3 (en) | 2009-07-16 |
BRPI0411721A (en) | 2006-05-23 |
FR2856685A1 (en) | 2004-12-31 |
CN1809560A (en) | 2006-07-26 |
ZA200600690B (en) | 2007-05-30 |
JP4629666B2 (en) | 2011-02-09 |
CA2531011C (en) | 2012-10-09 |
FR2856685B1 (en) | 2005-09-23 |
US7674803B2 (en) | 2010-03-09 |
US20070054939A1 (en) | 2007-03-08 |
AU2004253649B2 (en) | 2009-09-24 |
AU2004253649A1 (en) | 2005-01-13 |
MXPA05013521A (en) | 2006-03-09 |
AR044909A1 (en) | 2005-10-05 |
EP1636218A1 (en) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1636218B1 (en) | Thiazolylpiperidine derivatives as mtp inhibitors | |
US7723358B2 (en) | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | |
JP6948322B2 (en) | Heteroarylhydroxypyrimidinone as an APJ agonist of APJ receptor | |
JP6716711B2 (en) | 6-Hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamide as APJ agonist | |
US20100137601A1 (en) | Thiazolylimidazole derivatives an their use as inhibitors of microsomal triglyceride transfer protein | |
JP5424256B2 (en) | Derivatives of azabicyclooctane, process for producing the same and use thereof as inhibitors of dipeptidyl peptidase IV | |
CN102203101B (en) | Pyrrolo [2, 3-c] pyridine derivatives as p38 kinase inhibiting agents | |
US6399631B1 (en) | Carbazole neuropeptide Y5 antagonists | |
KR102204804B1 (en) | Dihydropyrazole gpr40 modulators | |
CN1264384A (en) | Fused 1,2,4-thiadiazine derivatives, their preparation method and use | |
JP2016504345A (en) | Protein kinase inhibitors | |
KR20120096540A (en) | Indole compound and pharmaceutical use thereof | |
JP2021517136A (en) | Substitution as TRK kinase inhibitor (2-azabicyclo [3.1.0] hexane-2-yl) pyrazolo [1,5-a] pyrimidine compound and substitution (2-azabicyclo [3.1.0] hexane-2) -Il) Imidazo [1,2-b] pyridazine compound | |
CN111419835A (en) | Application of benzenesulfonamide compound as mPGES-2 inhibitor and medicine | |
TW201031638A (en) | 4-aryl-butane-1,3-diamides | |
TWI752026B (en) | Certain protein kinase inhibitors | |
JPWO2005030773A1 (en) | New pyrazolopyrimidine derivatives | |
US6455532B1 (en) | Pyrazinone thrombin inhibitors | |
WO2019218904A1 (en) | Unnatural amino acid derivative, preparation method therefor and use thereof | |
HRP960375A2 (en) | Therapeutically active compounds | |
CN111892592B (en) | JAK kinase inhibitors and uses thereof | |
JP2010516661A (en) | Derivatives of pyrrolopyridine-2-carboxamide, their preparation and their therapeutic use | |
JP2019522651A (en) | Substituted pyrrolo [2,3-D] pyridazin-4-ones and pyrazolo [3,4-D] pyridazin-4-ones as protein kinase inhibitors | |
WO2023177568A1 (en) | Cannabinoid receptor modulating compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004735742 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12005502137 Country of ref document: PH Ref document number: 2420/KOLNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048157394 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/013521 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2531011 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007054939 Country of ref document: US Ref document number: 1020057024663 Country of ref document: KR Ref document number: 10561989 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006515818 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/00690 Country of ref document: ZA Ref document number: 2004253649 Country of ref document: AU Ref document number: 2006101890 Country of ref document: RU Ref document number: 200600690 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2004253649 Country of ref document: AU Date of ref document: 20040602 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057024663 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004735742 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0411721 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10561989 Country of ref document: US |